On December 10, 2014, a MSD Merck’s new generation of HPV vaccine, Gardasil 9, wins FDA approvals to prevent a certain cancer cased by 5 additional type of HPV.
Gardasil 9 has the potential to prevent approximately 90% of cervical, vulvar, vaginal and anal cancers. Gardasil 9 is a vaccine approved for use in females ages 9 through 26 and males ages 9 through 15.
This approved for the prevention of cervical, vulvar, vaginal and anal cancers caused by HPV types 16, 18, 31, 33, 45, 52 and 58, and for the prevention of genital warts caused by HPV 6 and 11.
Gardasil 9 is administered as three separate shorts with initial dose followed by additional shots given two and sex months later, exactly the same to current administration schedule of Gardasil 4.
For more details and more information, please CLICK HERE.